Adam Baker Lead the Human Health and Microbiome Research and Development team who are responsible for the research of current and next-generation probiotics, the development of technical in vitro and in vivo platforms for biomarker identification, and building a strong portfolio of scientific data to support our commercial probiotic business.
Alexandre Passioukov leads translational medicine efforts across oncology, CNS and dermatology therapeutic areas at Pierre-Fabre R&D. Previously, Dr. Passioukov was leading translational medicine programs at Roche (Switzerland) with a special focus on immune-oncology drugs. Prior to joining Roche, Alexandre served as Head of Translational Research at EORTC in Brussels, conducting structural translational medicine activities of European clinical research networks.
Dr Chrysi Sergaki is a scientist in the Microbiome section at the National Institute for Biological Standards and Control (NIBSC), working on microbial interactions and how to utilise them for the benefit of human health.
At NIBSC, Chrysi is leading projects investigating the role of the microbiome in gut health and disease. Furthermore, she is leading the development of reference reagents that can act as global standards and will be evaluated as candidates for the first World Health Organization Whole Cell Reference Reagents for the microbiome.
David Berry joined Flagship Pioneering in 2005 where he is a General Partner, focusing on conceiving, creating, resourcing, and launching groundbreaking companies. David has co-founded more than 20 companies across life sciences and sustainability, including Joule, Seres Therapeutics (NASDAQ: MCRB), T2 Biosystems (NASDAQ: TTOO), Indigo Agriculture, Evelo Biosciences, Eleven Biotherapeutics(NASDAQ: EBIO), LS9 (acquired by Renewable Energy Group), Axcella Health, and Inari Agriculture. He has served as founding CEO of over 10 companies including Seres, Evelo, and Axcella.
Professor Denise Kelly joined Seventure Partners, a European Leader in Venture Capital, in 2015 as an Investment Advisor to the Life Sciences Team and is focused specifically, on Human Microbiome investment opportunities, globally. Prior to joining Seventure, Denise was Head of her Research Lab at the World-renowned Rowett Institute, University of Aberdeen, where she acquired over 20 years experience in gut microbiology and immunology.
Eline is product manager Human Health at BaseClear and specialises in offering expert advice in refining research questions, hypotheses, consultancy in study design including sampling, analysing the microbial data and interpretation of the generated data. Eline has a strong background in human microbiome analysis, holding a PhD degree from Wageningen University in Microbial Eco-physiology of the human intestinal tract.
Dr Elinor McCartney has over 30 years’ experience in product development and EU regulatory affairs for multiple categories, including food and feed additives, novel foods and nutrition and health claims. Elinor is a graduate of the Royal (Dick) School of Veterinary Studies, University of Edinburgh, where she also obtained a PhD in enteric diseases of piglets. She has an MBA (with distinction) and has tutored Finance and Marketing for the Open University Business School.
Fabio Piccini is a broad-minded and innovative thinker and a focused and disciplined practitioner, with a PhD in Food, Nutrition and Health, further complemented by a wide-ranging portfolio of qualifications, professional memberships, preclinical and clinical research and published work. This is underpinned by twenty-nine years of counselling and consulting experience and teaching assignments at both under and postgraduate level.
Dr. ir. Frédéric Moens performed his PhD at the Research Group of Industrial Microbiology and Food Biotechnology of the Vrije Universiteit Brussel (Brussels, Belgium). His research dealt with the microbial metabolism and interactions in complex fermentation ecosystems, namely the human colon fermentation and cocoa bean fermentation processes.
Dr. Huiying Li is an Associate Professor in the Department of Molecular & Medical Pharmacology at University of California, Los Angeles. Dr. Li’s research focuses on the role of the skin microbiome in health and disease, including two most common skin diseases, acne vulgaris and atopic dermatitis.
With more than 20 years experience in the microbiota and microbiotics area, Jean-Pol G. Warzée, Medical Doctor has participated to many research and development projects in human health ( by elderly people, cystic fibrosis, …) and also in animal health in collaboration with Research Centers and Universities. Jean-pol has collaborated to the development of new microbiotics solutions and is author, co-author of many publications.
Lionel Breton got a PhD in 1982 in general Endocrinology in the lab of R.Michel and J.Roche at College de France in Paris. Than, he got a State Doctorate in general Pharmacology in Poitiers Hospital/ school of medicine in 1985 After a 1st position in Servier Laboratory as Project leader in neuro-pharmacology. He is also visiting Professor/affiliate member in the prestigious University McGill in Montreal.
Associate Professor and Senior Consultant Psychiatrist Magnus Sjogren received his doctoral training at University of Gothenburg, Sweden, and defended his PhD in 1999 (Clinical Psychiatry, University of Gothenburg). He undertook postdoctoral training at the Sahlgrens Academy, Sweden, and became Associate Professor in 2002. From 2003-2014 he had several senior positions in Pharma and biotech companies including Schering Plough and AstraZeneca and served as CMO for a stock-listed biotech company called DiaGenics in 2011-2014.
Momo Vuyisich is a founder and Chief Science Officer of Viome. He is also an Adjunct Professor at the University of New Mexico and New Mexico Tech. Besides providing scientific leadership at Viome, Momo focuses on product development, clinical certification, and clinical research.
Dr Guillaume Pavlovic is the Head of the mouse and rat model creation core & microbiota service at Institut Clinique de la Souris (ICS) – PHENOMIN. He direct the generation and validation of genetically rodent mutants and animal model microbiota research. He leads R&D programmes focusing on the development of new tools for genetic engineering and microbiota analyses, and is an expert in genetics and genome editing including the CRISPR/Cas system.
Per Falholt has an extensive experience in Life Science and Industrial Biotechnology and in bringing products to the market.
Leadership experience from tunning large global R&D organization and multiple customer collaboarations. Currently also involved in 3 start up companies within the field of gut and skin health
Peter Cartwright is the former Head of Research at Protexin (a manufacturer of probiotic supplements in the UK) and, for eight years, he oversaw research on probiotic strains. Screening more than 2,000 strains, Peter selected and acquired more than 100. He has degrees in Microbiology, Biomedicine, and Business Studies, and is the author of four books for the general public on intestinal health.
Veronika Oudova is a co-founder and Chief Executive Officer of S-Biomedic.
Veronika completed a master study in International Trade in Prague and a master in International Management within the program CEMS located in Prague, Vienna and Rotterdam. After her studies she has worked as project manager and marketing consultant at Cord Blood Bank Czech Republic. There she also co-founded a spin-off company StemCellPro.